Kezar Life Sciences, Inc. (KZR) financial statements (2022 and earlier)

Company profile

Business Address 4000 SHORELINE COURT, SUITE 300
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments208,355120,759128,975142,308140,447149,954157,471
Cash and cash equivalents62,88257,09426,38222,90821,22812,83317,296
Short-term investments145,47363,665102,593119,400119,219137,121140,175
Prepaid expense2,5703,1743,4562,4092,7332,5871,780
Other current assets7298209159611,6311,2701,312
Total current assets:211,654124,753133,346145,678144,811153,811160,563
Noncurrent Assets
Operating lease, right-of-use asset2,7142,8743,0273,1733,3143,4483,576
Property, plant and equipment3,2832,9803,0173,2043,4353,6693,902
Other noncurrent assets282282282282282282282
Total noncurrent assets:6,2796,1366,3266,6597,0317,3997,760
TOTAL ASSETS:217,933130,889139,672152,337151,842161,210168,323
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,0133,3944,8196,4675,3795,1574,034
Accounts payable2,0281,5431,6333,5782,3581,2851,007
Accrued liabilities4,9854443,1862,8893,0213,8723,027
Employee-related liabilities 1,407     
Other liabilities  714213142
Other undisclosed current liabilities1,1994,4781,1181,0801,0421,005969
Total current liabilities:8,2127,8725,9447,5616,4426,1935,045
Noncurrent Liabilities
Long-term debt and lease obligation12,8453,5363,8424,1394,4224,6944,960
Long-term debt, excluding current maturities9,622      
Operating lease, liability3,2233,5363,8424,1394,4224,6944,960
Other undisclosed noncurrent liabilities(3,223)(3,536)(3,842)(4,139)(4,422)(4,694)(4,960)
Total noncurrent liabilities:9,6223,5363,8424,139 4,6944,960
Total liabilities:21,05711,4089,78611,70010,86410,88710,005
Stockholders' equity
Stockholders' equity attributable to parent196,876119,481129,886140,637140,978150,323158,318
Common stock56494848464646
Additional paid in capital377,765286,069281,973279,747267,093265,472262,041
Accumulated other comprehensive income (loss)(291)(195)(155)(140)(137)(112)25
Accumulated deficit(180,654)(166,442)(151,980)(139,018)(126,024)(115,083)(103,794)
Total stockholders' equity:196,876119,481129,886140,637140,978150,323158,318
TOTAL LIABILITIES AND EQUITY:217,933130,889139,672152,337151,842161,210168,323

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Operating expenses(14,103)(14,499)(13,009)(13,048)(11,068)(11,551)(9,853)
Operating loss:(14,103)(14,499)(13,009)(13,048)(11,068)(11,551)(9,853)
Other undisclosed loss from continuing operations before equity method investments, income taxes(159)      
Loss before gain (loss) on sale of properties:(14,262)(14,499)(13,009)(13,048)(11,068)(11,551)(9,853)
Other undisclosed net income50  54127  
Net loss:(14,212)(14,499)(13,009)(12,994)(10,941)(11,551)(9,853)
Other undisclosed net income attributable to parent 3747  262353
Net loss available to common stockholders, diluted:(14,212)(14,462)(12,962)(12,994)(10,941)(11,289)(9,500)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(14,212)(14,499)(13,009)(12,994)(10,941)(11,551)(9,853)
Comprehensive loss:(14,212)(14,499)(13,009)(12,994)(10,941)(11,551)(9,853)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(96)(3)32(3)(25)125500
Comprehensive loss, net of tax, attributable to parent:(14,308)(14,502)(12,977)(12,997)(10,966)(11,426)(9,353)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: